Gene therapy track continues to heat up: big money to enter, the future can be expected

On October 26th Bayer announced the acquisition of AskBio Pharmaceutical, a veteran gene therapy company, for $2bn in cash advances, in a deal that also included up to $2bn in potential mileage.
the acquisition will power Bayer's cell and gene therapy platform, which will see AskBio operate as an independent company.
AskBio was co-founded in 2001 by Dr. Jude Samulski, Dr. Xiao Xiao and Dr. Sheila Mikhail of AAV, focusing on the development and production of gene therapies for a wide range of genetic diseases, including neuromuscular, central nervous system, cardiovascular, respiratory and metabolic diseases.
source: AskBio's official website, in addition to Bayer's big deal, and pharmaceutical giant Roche have recently made a big deal in gene therapy.
won Spark Therapeutics, a gene therapy company, for $4.3 billion in February and a $1.15 billion gene therapy license agreement with Sarepta Therapeutics in December of that year.
the latest deal announced on October 14th, Roche struck a $1.8 billion partnership with Dyno Therapeutics to develop AAV vectors for targeted gene therapy for the central nervous system and liver using Dyno's AAV technology platform.
of big deals with the tech giants has warmed up the gene therapy circuit, followed by a funding boom for gene therapy companies.
Since June, global gene therapy companies have raised more than $2 billion (including IPOs), according to the PharmaInvest database (see table below), with Boa's and Jiain Bio completing round b financings.
since June this year, gene therapy companies have focused on most of the diseases in the field of genetic diseases (/ on behalf of unresourced details of the round) (Source: PharmaInvest)
, Poseida Therapeutics announced an IPO to raise $224 million, half a month after completing its $110 million round of D-round financing.
Poseida's Cas-CLOVER technology is somewhat different in the field of gene therapy development for AAV vector delivery and CRISPR gene editing technology.
This technique, considered an advanced alternative to CRISPR-Cas9, combines the advantages of the first generation of CRISPR (easy to design, low cost, versatile) with the specificity of a single-origin cynogeneic binary nuclease system (e.g. TALEN) with the advantages of high fidelity and efficient editing efficiency, while no off-target effects were detected in preclinical studies conducted in Poseida.
, Poseida is actively expanding the scope of application of this technology.
Cas-CLOVER Technology (Source: Poseida) Taysha Gene Therapies also raised $277m in two months ($96m in round B and $181m in IPOs), noting that Taysha had just announced its creation in April (seed round raised $30m) and that the company's pipeline was very luxurious, including 18 in gene therapy.
source: Taysha's official website has won the Nobel Prize for gene editing technology CRISPR, and the field of gene therapy is still heating up.
with the continuous improvement of existing technology, new technology continues to develop, in the capital market driven by enthusiasm, gene therapy can usher in the spring, bring about a medical revolution, very much look forward to.
: 1 s Bayer AskBio to Broad Innovation Base in Cell and Gene Therapy (Source: AskBio) 2 s Poseidas Therapeutics Announces Pricing to Initial Public Offering (Source: News Agency)